These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 27268749)

  • 41. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
    Ma XM; Han YW; Zhang J; Cui WJ; Wang X
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR
    Kar A; Koto K; Walker D; Trudeau T; Edgerton S; Thor A; Gutierrez-Hartmann A
    Breast Cancer Res Treat; 2020 Aug; 182(3):601-612. PubMed ID: 32562116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
    Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
    Nguyen TH; Nguyen VH; Nguyen TL; Qiuyin C; Phung TH
    Biomed Res Int; 2019; 2019():7391237. PubMed ID: 31583246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast.
    Negi P; Kingsley PA; Jain K; Sachdeva J; Srivastava H; Marcus S; Pannu A
    Asian Pac J Cancer Prev; 2016; 17(8):3911-6. PubMed ID: 27644638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
    Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
    Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.
    Idirisinghe PK; Thike AA; Cheok PY; Tse GM; Lui PC; Fook-Chong S; Wong NS; Tan PH
    Am J Clin Pathol; 2010 Mar; 133(3):416-29. PubMed ID: 20154280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
    Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical features and survival analysis of very young (age<35) breast cancer patients.
    Wei XQ; Li X; Xin XJ; Tong ZS; Zhang S
    Asian Pac J Cancer Prev; 2013; 14(10):5949-52. PubMed ID: 24289606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.